Alyeska Investment Group
AUTL

Alyeska Investment Group’s Autolus Therapeutics AUTL Stock Holding History

Alyeska Investment Group’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-214,300
Closed -$394K – 542
2023
Q1 		$394K Sell
214,300
-1,250,000
-85% -$2.44M ﹤0.01% 421
2022
Q4 		$2.78M Buy
+1,464,300
New +$3.7M 0.03% 299
2021
Q3 		– Sell
-208,706
Closed -$1.39M – 682
2021
Q2 		$1.39M Hold
208,706
– – 0.02% 562
2021
Q1 		$1.2M Buy
208,706
+42,897
+26% +$318K 0.02% 541
2020
Q4 		$1.48M Sell
165,809
-1,327
-0.8% -$14.1K 0.02% 394
2020
Q3 		$1.95M Sell
167,136
-101,900
-38% -$1.48M 0.03% 357
2020
Q2 		$4.31M Sell
269,036
-37,821
-12% -$419K 0.07% 281
2020
Q1 		$1.84M Buy
306,857
+99,546
+48% +$920K 0.04% 264
2019
Q4 		$2.74M Buy
207,311
+33,344
+19% +$436K 0.04% 273
2019
Q3 		$2.16M Buy
173,967
+75,000
+76% +$991K 0.03% 284
2019
Q2 		$1.59M Buy
+98,967
New +$2.21M 0.02% 341
2018
Q4 		– Sell
-46,500
Closed -$1.43M – 365
2018
Q3 		$1.43M Sell
46,500
-78,500
-63% -$2.12M 0.02% 325
2018
Q2 		$3.35M Buy
+125,000
New +$3.3M 0.03% 307

Other funds holding AUTL

SP
Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
PL
Perpetual Ltd Sydney, New South Wales, Australia $7B AUM 19.75% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Alyeska Investment Group's AUTL Position: Q2 2023 in Review

Alyeska Investment Group sold out of Autolus Therapeutics (AUTL) in Q2 2023, closing a stake of 214,300 shares — an estimated $394K sold.

Alyeska Investment Group first reported a position in AUTL in Q2 2018 and held it in 13 quarters. The position peaked at $4.31M in Q2 2020. 69 funds tracked by Wall St. Rank hold AUTL as of Q2 2023.

  • Alyeska Investment Group reported no remaining Autolus Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Alyeska Investment Group sold 214,300 Autolus Therapeutics shares in Q2 2023, an estimated $394K.
  • Alyeska Investment Group first reported a position in Autolus Therapeutics in Q2 2018 and held it in 13 quarters.
  • Alyeska Investment Group's Autolus Therapeutics position peaked at $4.31M in Q2 2020.
  • 69 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q2 2023.

Based on Alyeska Investment Group's 13F filing for Q2 2023, filed 14 Aug 2023.